A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia Patients

Completed

Conditions studied: Acute Lymphoblastic Leukemia

In brief

The aim of this study was to collect existing information from the medical charts of patients enrolled in the ongoing asciminib Managed Access Program (MAP) to better understand the effectiveness and safety of asciminib when used to treat adult patients with Ph+ ALL who are refractory, resistant or intolerant to available treatments.

Key facts

Study ID

NCT07644351

Run by

Novartis Pharmaceuticals

People needed

37

Starts

2024-12-16

Expected to finish

2025-09-17

Last updated by the study team

2026-06-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients enrolled in the asciminib MAP.
• Diagnosis of Ph+ ALL.
• Patients received at least one dose of asciminib through the asciminib MAP.
• Appropriate approval obtained for the use of patient data including:
• Signed informed consent form (ICF), or
• ICF waiver granted by an Institutional review board/Independent Ethics Committee (IRB/IEC).

You may not qualify if…

• Age < 18 years at the time of initiating asciminib treatment.

Where it is running

• Novartis Investigative Site — Boston, Massachusetts, United States
• Novartis Investigative Site — Sydney, New South Wales, Australia
• Novartis Investigative Site — Montreal, Canada
• Novartis Investigative Site — Hong Kong, China
• Novartis Investigative Site — Le Chesnay, France
• Novartis Investigative Site — Ramat Gan, Israel
• Novartis Investigative Site — Ascoli Piceno, Italy
• Novartis Investigative Site — Bari, Italy
• Novartis Investigative Site — Catania, Italy
• Novartis Investigative Site — Cuneo, Italy
• Novartis Investigative Site — Pescara, Italy
• Novartis Investigative Site — Torino, Italy
• Novartis Investigative Site — Rotterdam, Netherlands
• Novartis Investigative Site — Islamabad, Pakistan
• Novartis Investigative Site — Rawalpindi, Pakistan
• Novartis Investigative Site — Bialystok, Poland
• Novartis Investigative Site — Madrid, Spain
• Novartis Investigative Site — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.